Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study

Table 3 Median change from baseline in EQ-5D index score

Visit	Total study cohort (n = 1581)	Group A	Group B	Group C	Group D
		Recent prior fracture^a; incident fracture (n = 119)	Recent prior fracture^a; no incident fracture (n = 646)	No recent prior fracture^a; incident fracture (n = 89)	No recent prior fracture^a; no incident fracture (n = 727)
3 months	0.07 (0.00, 0.37)	0.07 (0.00, 0.50)	0.10 (0.00, 0.51) ^‡	0.04 (0.00, 0.27)	0.04 (0.00, 0.27)
6 months	0.11 (0.00, 0.46)	0.10 (0.00, 0.53)	0.14 (0.00, 0.53) ^†	0.04 (0.00, 0.26)	0.11 (0.00, 0.41)
12 months	0.12 (0.00, 0.46)	0.17 (0.00, 0.60) ^*	0.14 (0.00, 0.53) ^†	0.04 (−0.05, 0.27) ^#	0.11 (0.00, 0.43)
18 months	0.15 (0.00, 0.50)	0.17 (−0.03, 0.57)	0.20 (0.00, 0.53) ^†	0.04 (−0.04, 0.40)	0.13 (0.00, 0.43)
24 months	0.17 (0.00, 0.47)	0.10 (−0.04, 0.50) ^§	0.21 (0.00, 0.57) ^{†, ‡}	0.11 (−0.07, 0.33)	0.11 (0.00, 0.38)
36 months	0.17 (0.00, 0.48)	0.15 (−0.07, 0.60)	0.20 (0.00, 0.57) ^†	0.09 (0.00, 0.33)	0.16 (0.00, 0.38)

^aRecent prior fracture within the last 12 months before baseline visit.
Data given in brackets are the interquartile range (Q1, Q3).
All p < 0.05 for within-group change from baseline (Wilcoxon signed rank test).
Between group comparisons at each visit (Wilcoxon rank-sum tests, Bonferroni adjusted p-values).
^* p < 0.05 for pairwise comparison of group A versus group C.
^† p < 0.05 for pairwise comparison of group B versus group C.
^‡ p < 0.05 for pairwise comparison of group B versus group D.
^# p < 0.05 for pairwise comparison of group C versus group D.
^§ p < 0.05 for pairwise comparison of group A versus group B.

ISSN: 1471-2474